Back Login to subscribe 🔔 Set Alert

MRNA Moderna, Inc. Common Stock

15 min delay
Today's News Sentiment
Loading...
Upcoming Earnings
Loading...
MRNA Fundamental Data
Loading...
Similar Companies
Loading...
MRNA Options Chain
Put/Call Ratio
-
-
Expected Move
-
-
Max Pain
-
-
ATM Call Break-even
-
-
ATM Put Break-even
-
-
Loading options…
CALLS
Strike Last Bid Ask Mark IV Volume OI Δ Delta Θ Theta
PUTS
Strike Last Bid Ask Mark IV Volume OI Δ Delta Θ Theta
MRNA Insider Transactions
Loading insider data…
MRNA News
Date Headline Sentiment
Merck And Moderna Announce Topline Results From The Phase 3 Interpath-001 Trial Evaluating Adjuvant Treatment With Intismeran Autogene In Combination With KEYTRUDA In Patients With Completely Resected Stage IIB-IV Melanoma; At A Pre-specified Interim Analysis, Intismeran In Combination With KEYTRUDA As Adjuvant Therapy Demonstrated Statistically Significant And Clinically Meaningful Improvements In RFS And DMFS Compared To KEYTRUDA Alone
70.88%
Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All Children
86.07%
Beyond COVID: Moderna Wins FDA Approval for Its Seasonal Flu Vaccine
80.47%
Moderna shares are trading higher after the company announced FDA approval for mFLUSIVA.
94.85%
Reported Earlier, Moderna's mFLUSIVA Wins FDA Approval As First mRNA-Based Flu Vaccine For Adults 50 And Older
91.1%
Moderna Advances Ebola Vaccine Into Human Testing
91.98%
Moderna Vaccinates First Patients In Its Phase 1 Clinical Trial Of mRNA-1469 To Treat Bundibugyo Ebolavirus Following Health Canada Approval
58.77%
Citigroup Maintains Neutral on Moderna, Raises Price Target to $60
49.26%
Moderna shares are trading lower after the company announced that its norovirus vaccine candidate, mRNA-1403, did not meet Phase 3 success criteria and it is preparing to enrol an additional cohort.
97.18%
Moderna Burns Cash, Suffers Fresh Vaccine Setback
96.96%